|
|
Dyne Therapeutics Inc (NASDAQ: DYN) |
|
Price: $16.1300
$-0.10 
-0.616%
|
| Day's High:
| $16.246000289916992
| Week Perf:
| -5.73 %
|
| Day's Low: |
$ 15.88 |
30 Day Perf: |
-38.76 % |
| Volume (M): |
231,717 |
52 Wk High: |
$ 28.50 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$19.41 |
| Open: |
$16.10 |
52 Wk Low: |
$11.92 |
|
|
| Market Capitalization (Millions $) |
2,669 |
| Shares
Outstanding (Millions) |
165 |
| Employees |
258 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-519 |
| Cash Flow (TTM) (Millions $) |
268 |
| Capital Exp. (TTM) (Millions $) |
21 |
Business Description
The company conducts research and development programs, preclinical studies, and clinical trials to develop product candidates. It plans to submit applications for regulatory approvals and intends to commercialize any approved product candidates, utilizing its FORCE platform and emphasizing intellectual property protection and commercialization strategies.
Company Address: 1560 Trapelo Road Waltham 2451 MA
Company Phone Number: 786-8230 Stock Exchange / Ticker: NASDAQ DYN
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Clinical Study
Published Tue, Oct 7 2025 10:15 AM UTC
BackgroundNeuromuscular diseases such as Myotonic Dystrophy Type 1 (DM1) and Duchenne Muscular Dystrophy (DMD) present significant challenges for patients and clinicians alike. These conditions are characterized by progressive muscle weakness, leading to substantial disability and reduced quality of life. Innovations in therapeutic strategies are crucial to mitigate the imp...
|
| Clinical Study
Published Tue, Sep 3 2024 10:30 AM UTC
Dyne Therapeutics, a biotechnology company dedicated to creating transformative therapies for patients with serious muscle diseases, has announced significant advancements across multiple clinical programs. The company is reporting groundbreaking data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy (DMD), demonstrating unprecedented dystrophin ex...
|
| Clinical Study
Published Mon, Jun 24 2024 11:30 AM UTC
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe DiseaseWALTHAM, Mass., June 24, 2024 - Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company, has announced new preclinical data that showcase the potential of their FORCE platform to deliv...
|
| Financing Agreement
Published Tue, May 28 2024 11:30 AM UTC
Dyne Therapeutics Raises $374.3 Million in Public Offering, Continues to Advance Innovation in Muscle Disease Therapeutics
Dyne Therapeutics Inc. announces the successful closing of its underwritten public offering of 12,075,000 shares of common stock at a price of $31.00 per share, generating approximately $374.3 million in gross proceeds. This includes the full exercis...
|
| Shares
Published Wed, May 22 2024 12:40 AM UTC
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
WALTHAM, Mass., May 21, 2024 Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company, has recently disclosed the pricing details for its upcoming underwritten public offering. The company aims to sell 10,500,000 shares of its common stock, with each share priced...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
0.03 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
1.62 $ |
| Cash |
5.43 $
|
| Book Value |
4.24 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
- |
| Net
Income per Employee (TTM) |
-2,013,202 |
| Receivable Turnover Ratio (TTM) |
- |
| Inventory Turnover Ratio (TTM) |
- |
| Asset Turnover Ratio (TTM) |
- |
|
|
| Per Share |
|
| Earnings (TTM) |
0.03 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
1.62 $ |
| Cash |
5.43 $
|
| Book Value |
4.24 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
On May 19 2024 the Dyne Therapeutics Inc provided following guidance
Dyne Therapeutics, a leading muscle disease company, has announced that it will be hosting a virtual investor event tomorrow, May 20 at 8:00 a.m. ET to review new clinical data from its Phase 1/2 ACHIEVE and DELIVER trials. The company, based in Waltham, Mass., has adjusted its timeline to report this data sooner than originally anticipated, providing an update on its progress.
The event will focus on the efficacy and safety data from these trials, which are crucial in advancing the development of innovative therapeutics for individuals with genetically driven diseases. Dynes Therapeutics is dedicated to transforming the lives of patients through its groundbreaking research and development efforts.
|
|
|
